Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Haanen

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 22, 2024
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation TherapiesJohn Haanen, Christy Los, Giao Q Phan, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitorsBenjamin Switzer, John Haanen, Paul C Lorigan, et al.
Cancer Treatment Reviews|December 21, 2022
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?Dimitrios C Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Urology|August 2, 2011
A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situAxel Bex, Christian Blank, Wim Meinhardt, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLCMarjolein Metselaar-Albers, Irma Meijerman, Ferdi Engels, et al.
World Journal of Urology|February 3, 2016
Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapyAllard Noe, Roderick E de Bruijn, Christian Blank, et al.
Angiogenesis|April 13, 2017
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancerTeele Kuusk, Laurence Albiges, Bernard Escudier, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumorAxel Bex, Henk Mallo, Martijn Kerst, et al.
BMC Cancer|August 2, 2020
Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectivenessMelanie Lindenberg, Valesca Retèl, Maartje Rohaan, et al.
Journal for Immunotherapy of Cancer|October 17, 2020
Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapyDimitrios C Ziogas, Frosso Kostantinou, Evangelos Cholongitas, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 22, 2024
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation TherapiesJohn Haanen, Christy Los, Giao Q Phan, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitorsBenjamin Switzer, John Haanen, Paul C Lorigan, et al.
Cancer Treatment Reviews|December 21, 2022
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?Dimitrios C Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Urology|August 2, 2011
A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situAxel Bex, Christian Blank, Wim Meinhardt, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLCMarjolein Metselaar-Albers, Irma Meijerman, Ferdi Engels, et al.
World Journal of Urology|February 3, 2016
Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapyAllard Noe, Roderick E de Bruijn, Christian Blank, et al.
Angiogenesis|April 13, 2017
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancerTeele Kuusk, Laurence Albiges, Bernard Escudier, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumorAxel Bex, Henk Mallo, Martijn Kerst, et al.
BMC Cancer|August 2, 2020
Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectivenessMelanie Lindenberg, Valesca Retèl, Maartje Rohaan, et al.
Journal for Immunotherapy of Cancer|October 17, 2020
Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapyDimitrios C Ziogas, Frosso Kostantinou, Evangelos Cholongitas, et al.
Pageof 7